Quantitative Analysis of α-L-Iduronidase Expression in Immunocompetent Mice Treated with the Sleeping Beauty Transposon System

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Aronovich, Elena L ^a   Hall, Bryan C ^a   Bell, Jason B ^a   McIvor, R Scott ^a   Hackett, Perry B ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; LEVO IDURONIDASE; SB100X PROTEIN; TRANSPOSASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DNA TRANSPOSITION; ENZYME ACTIVITY; ENZYME STABILITY; FEMALE; GENDER BIAS; GENE CONTROL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE INACTIVATION; GENE LOSS; GENE THERAPY; GENETIC VARIABILITY; HYDRODYNAMICS BASED TRANSFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; PLASMID; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SLEEPING BEAUTY TRANSPOSON SYSTEM; STANDARD; TRANSGENE;

ANIMALS; DNA TRANSPOSABLE ELEMENTS; FEMALE; IDURONIDASE; IMMUNOCOMPETENCE; LIVER; MALE; MICE; TRANSGENES;

EID: 84886917002     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078161     Document Type: Article

References (34)

1. Ivics Z, Hackett PB, Plasterk RH, Izsvák Z, (1997) Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91: 501-510. doi:10.1016/S0092-8674(00)80436-5. PubMed: 9390559.
2. Izsvák Z, Hackett PB, Cooper LJ, Ivics Z, (2010) Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays 32: 756-767. doi:10.1002/bies.201000027. PubMed: 20652893.
3. Aronovich EL, McIvor RS, Hackett PB, (2011) The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet 20(R1):: 14-20. doi:10.1093/hmg/ddr140.
4. Hackett PB Jr, Aronovich EL, Hunter D, Urness M, Bell JB, et al. (2011) Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther 11: 341-349. doi:10.2174/156652311797415827. PubMed: 21888621.
5. Hackett PB, Largaespada DA, Cooper LJN, (2010) A transposon and transposase system for human application. Mol Ther 18: 674-683. doi:10.1038/mt.2010.2. PubMed: 20104209.
6. Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, et al. (2000) Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 25: 35-41. doi:10.1038/75568. PubMed: 10802653.
7. Aronovich EL, Bell JB, Belur LR, Gunther R, Koniar B, et al. (2007) Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med 9: 403-415. doi:10.1002/jgm.1028. PubMed: 17407189.
8. Aronovich EL, Bell JB, Khan SA, Belur LR, Gunther R, et al. (2009) Systemic correction of storage disease in MPS I NOD/SCID mice using the Sleeping Beauty transposon system. Mol Ther 17: 1136-1144. doi:10.1038/mt.2009.87. PubMed: 19384290.
9. Chen ZY, He CY, Ehrhardt A, Kay MA, (2003) Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8: 495-500. doi:10.1016/S1525-0016(03)00168-0. PubMed: 12946323.
10. Neufeld EF, Muenzer J, (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, eds. The Metabolic and Molecular Bases of Inherited Disease. Vol. III. 8th edn. New York: McGraw-Hill. pp.: 3427-3436.
11. Izsvák Z, Stüwe EE, Fiedler D, Katzer A, Jeggo PA, et al. (2004) Healing the wounds inflicted by Sleeping Beauty transposition by double-strand break repair in mammalian somatic cells. Mol Cell 13: 279-290. doi:10.1016/S1097-2765(03)00524-0. PubMed: 14759372.
12. Plasterk RHA, Izsvák Z, Ivics Z, (1999) Resident aliens: the Tc1/mariner superfamily of transposable elements. Trends Genet 15: 326-332. doi:10.1016/S0168-9525(99)01777-1. PubMed: 10431195.
13. Geurts AM, Yang Y, Clark KJ, Liu G, Cui Z, et al. (2003) Gene transfer into genomes of human cells by the Sleeping Beauty transposon system. Mol Ther 8: 108-117. doi:10.1016/S1525-0016(03)00099-6. PubMed: 12842434.
14. Yant SR, Park J, Huang Y, Mikkelsen JG, Kay MA, (2004) Mutational analysis of the N-terminal DNA-binding domain of Sleeping Beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol Cell Biol 24: 9239-9247. doi:10.1128/MCB.24.20.9239-9247.2004. PubMed: 15456893.
15. Mátés L, Chuah MK, Belay E, Jerchow B, Manoj N, et al. (2009) Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 41: 753-761. doi:10.1038/ng.343. PubMed: 19412179.
16. Cui Z, Geurts AM, Liu G, Kaufman CD, Hackett PB, (2002) Structure-function analysis of the inverted terminal repeats of the Sleeping Beauty transposon. J Mol Biol 318: 1221-1235. doi:10.1016/S0022-2836(02)00237-1. PubMed: 12083513.
17. Zayed H, Izsvák Z, Walisko O, Ivics Z, (2004) Development of hyperactive Sleeping Beauty transposon vectors by mutational analysis. Mol Ther 9: 292-304. doi:10.1016/j.ymthe.2004.06.690. PubMed: 14759813.
18. Ammar I, Izsvák Z, Ivics Z, (2012) The Sleeping Beauty transposon toolbox. Methods Mol Biol 859: 229-240. doi:10.1007/978-1-61779-603-6_13. PubMed: 22367875.
19. Bell JB, Aronovich EL, Schreifels JM, Beadnell TC, Hackett PB, (2010) Duration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery. Mol Ther 18: 1796-1802. doi:10.1038/mt.2010.152. PubMed: 20628359.
20. Arruda VR, Favaro P, Finn JD, (2009) Strategies to modulate immune responses: a new frontier for gene therapy. Mol Ther 17: 1492-1503. doi:10.1038/mt.2009.150. PubMed: 19584819.
21. Okuyama T, Huber RM, Bowling W, Pearline R, Kennedy SC, et al. (1996) Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alpha 1-antitrypsin in vivo. Hum Gene Ther 7: 637-645. doi:10.1089/hum.1996.7.5-637. PubMed: 8845389.
22. Miao CH, Ohashi K, Patijn GA, Meuse L, Ye X, et al. (2000) Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther 1: 522-532. doi:10.1006/mthe.2000.0075. PubMed: 10933977.
23. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347. doi:10.1038/nm1358. PubMed: 16474400.
24. Liu G, Cui Z, Aronovich EL, Whitley CB, Hackett PB, (2003) Excision of Sleeping Beauty transposons: parameters and applications to gene therapy. J Gene Med 6: 574-583. PubMed: 15133768.
25. Chen ZY, Riu E, He CY, Xu H, Kay MA, (2008) Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther 16: 548-556. doi:10.1038/sj.mt.6300399. PubMed: 18253155.
26. Osborn MJ, McElmurry RT, Lees CJ, DeFeo AP, Chen ZY, et al. (2011) Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther 19: 450-460. doi:10.1038/mt.2010.249. PubMed: 21081900.
27. Gracey Maniar LE, Maniar JM, Chen ZY, Lu J, Fire AZ, et al. (2013) Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Mol Ther 21: 131-138. doi:10.1038/mt.2012.244. PubMed: 23183534.
28. Lu J, Zhang F, Kay MA, (2013) A Mini-intronic Plasmid (MIP): A Novel Robust Transgene Expression Vector In Vivo and In Vitro. Mol Ther 21: 954-963. doi:10.1038/mt.2013.33. PubMed: 23459514.
29. Score PR, Belur LR, Frandsen JL, Geurts JL, Yamaguchi T, et al. (2006) Sleeping Beauty-mediated transposition and long-term expression in vivo: use of the Lox/Cre recombinase system to distinguish transposition-specific expression. Mol Ther 13: 617-624. doi:10.1016/j.ymthe.2005.10.015. PubMed: 16356773.
30. Miner NA, Koehler J, Greenaway L, (1969) Intraperitoneal injection of mice. Appl Microbiol 17: 250-251. PubMed: 5775909.
31. Gaines Das R, North D, (2007) Implications of experimental technique for analysis and interpretation of data from animal experiments: outliers and increased variability resulting from failure of intraperitoneal injection procedures. Lab Anim 41: 312-320. doi:10.1258/002367707781282802. PubMed: 17640458.
32. Podetz-Pedersen KM, Bell JB, Steele TW, Wilber A, Shier WT, et al. (2010) Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons. Hum Gene Ther 21: 210-220. doi:10.1089/hum.2009.128. PubMed: 19761403.
33. Bell JB, Podetz-Pedersen KM, Aronovich EL, Belur LR, McIvor RS, et al. (2007) Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. Nat Protoc 2: 3153-3165. doi:10.1038/nprot.2007.471. PubMed: 18079715.
34. Garcia-Rivera MF, Colvin-Wanshura LE, Nelson MS, Nan Z, Khan SA, et al. (2007) Characterization of an immunodeficient mouse model of mucopolysaccharidosis type 1 suitable for preclinical testing of human stem cell and gene therapy. Brain Res Bullet 74: 429-438. doi:10.1016/j.brainresbull.2007.07.018.